CTOs on the Move

Oratech

www.oratech.com

 
Oratech is a South Jordan, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.oratech.com
  • 475 W 10200 S
    South Jordan, UT USA 84095
  • Phone: 801.619.0282

Executives

Name Title Contact Details

Similar Companies

Detroit Wayne Mental Health Authority

DWIHN provides support to children with serious emotional disturbance, people with mental illness, developmental disability and/or substance use disorder.

Agile Therapeutics

Agile Therapeutics is a forward-thinking women`s healthcare company dedicated to fulfilling the unmet health needs of today`s women. Twirla® (levonorgestrel and ethinyl estradiol) transdermal system and our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Twirla® and our pipeline products are based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin.

Clinigen Group

Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Companys principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through ...

Opko

OPKO Health is a diversified healthcare company that seeks to establish industry leading positions in large, rapidly growing markets. Our diagnostics business includes BioReference Laboratories, the nation`s third largest clinical laboratory with a core genetic testing business and a 400 person sales and marketing team to drive growth and leverage new products, including the 4Kscore® prostate cancer test and the Claros® 1 in office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-¬4 CKD patients with vitamin D insufficiency (launched in November 2016), VARUBITM for chemotherapy induced nausea and vomiting (oral formulation launched by partner TESARO and IV formulation pending FDA approval), OPK88004, a once or twice weekly oxyntomodulin for type 2 diabetes and obesity, in Phase 2 clinical trials, among the new class of GLP-¬1 glucagon receptor dual agonists, and OPK88003, a selective androgen receptor modulator for benign prostatic hyperplasia (Phase 2). Our biologics business includes hGH-¬CTP, a once weekly human growth hormone in Phase 3 and partnered with Pfizer; and a long-¬acting Factor VIIa drug for hemophilia in Phase 2a.

Vindico Medical Education

Vindico Medical Education is a Thorofare, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.